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AnakinraHyperimmunoglobulinemia D and periodic fever syndrome (HIDS;MIM# 260920) is a rare recessively-inherited
autoinﬂammatory condition caused bymutations in theMVK gene, which encodes for mevalonate kinase, an es-
sential enzyme in the isoprenoid pathway. HIDS is clinically characterized by recurrent episodes of fever and in-
ﬂammation. Here we report on the case of a 2 year-old Portuguese boy with recurrent episodes of fever, malaise,
massive cervical lymphadenopathy and hepatosplenomegaly since the age of 12 months. Rash, arthralgia, ab-
dominal pain and diarrhea were also seen occasionally. During attacks a vigorous acute-phase response was de-
tected, including elevated erythrocyte sedimentation rate, C-reactive protein, serum amyloid A and leukocytosis.
Clinical and laboratory improvement was seen between attacks. Despite normal serum IgD level, HIDS was clin-
ically suspected. Mutational MVK analysis revealed the homozygous genotype with the novel p.Arg277Gly
(p.R277G) mutation, while the healthy non-consanguineous parents were heterozygous. Short nonsteroidal
anti-inﬂammatory drugs and corticosteroid courses were given during attacks with poor beneﬁts, whereas
anakinra showed positive responses only at high doses. The p.R277Gmutation here described is a novelmissense
MVKmutation, and it has been detected in this case with a severe HIDS phenotype. Further studies are needed to
evaluate a co-relation genotype, enzyme activity and phenotype, and to deﬁne the best therapeutic strategies.
© 2014 Elsevier B.V. All rights reserved.1. Introduction
Hyperimmunoglobulinemia D and periodic fever syndrome (HIDS;
MIM# 260920) is a rare autosomal recessive autoinﬂammatory condition
caused by mutations in theMVK gene, which encodes for mevalonate ki-
nase, an essential enzyme in the isoprenoid and cholesterol biosynthesisntineutrophil cytoplasmic anti-
erentiation; cm, centimeter(s);
iter(s); DNA, deoxyribonucleic
s, extractable nuclear antigens;
), glycine; h, hour; H, histidine;
Hyperimmunoglobulinemia D
ency virus; I, isoleucine; Ig, im-
; MA, mevalonic aciduria; mg,
illimeter(s); mm3, cubic milli-
onsteroidal anti-inﬂammatory
amyloid A; sc, subcutaneous;
onine; TNF, tumor necrosis fac-
ntro Hospitalar Lisboa Central,
s), JIAROSTE@clinic.ub.es
nceicaoneves59@gmail.compathway (Bader-Meunier et al., 2011; Korppi et al., 2011; van der Hilst
and Frenkel, 2010). The disease is clinically characterized by recurrent
episodes of fever and inﬂammation. Starting in the ﬁrst year of life, pa-
tients have periodic fever episodes lasting four to six days, at variable in-
tervals, with accompanying lymphadenopathy, hepatosplenomegaly,
gastrointestinal complaints, aphthous ulcers, arthralgias, and skin rashes
(Bader-Meunier et al., 2011; Korppi et al., 2011; Lierl, 2007; van der
Burgh et al., 2012; van der Hilst and Frenkel, 2010). Some episodes are
triggered by immunizations, stress, infection, or minor trauma (Korppi
et al., 2011; van der Hilst and Frenkel, 2010). AA-type amyloidosis has
been very rarely reported in HIDS patients, with less than 10 cases
currently described, an incidence considerably lower than that found
in other inherited autoinﬂammatory syndromes (van der Hilst and
Frenkel, 2010). Laboratory evaluation at the time of attack reveals a vigor-
ous acute phase response, with elevated erythrocyte sedimentation rate
(ESR), granulocytosis, raised serum concentrations of C-reactive protein
(CRP) and serum amyloid A (SAA). Polyclonal serum IgD elevation has
been considered the hallmark of the disease. However, the serum IgD el-
evation is not obligatory and IgD values may be normal, especially in
young children. Serum IgA levels are also often elevated in most patients
with HIDS. During attacks, mevalonic acid urinary excretion is slightly el-
evated, and its measurement can be of diagnostic value (Bader-Meunier
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other hand, cellular and humoral immunity tests, as well as serum com-
plement levels, are normal in HIDS patients, with undetected autoanti-
bodies (Lierl, 2007). Currently, there is no evidence-based treatment
available for HIDS (Korppi et al., 2011). Thus far, some children have
been successfully treated with etanercept and others with IL-1 antago-
nists (Bodar et al., 2011; Caorsi et al., 2012; Galeotti et al., 2012;
Hoffman, 2009; Rigante et al., 2006).Fig. 1.Chromatograms showing thepatient's homozygousp.Arg277Gly/p-Arg277GlyMVK
genotype (bottom panel), the heterozygous p.Arg277Gly/wt MVK genotype of patient's
parents (middle panel) and a healthy control (upper panel).2. Clinical report
A 2 year-old Portuguese boy, with age-appropriate weight (75th
percentile) and height (75th percentile), and normal cognitive develop-
ment, presented with recurrent episodes of fever (3–5-day duration,
every 2–5 weeks) and malaise, massive cervical lymphadenopathy
and hepatosplenomegaly (6–7 cm), since the age of 12 months. Before
diagnosis, three severe attacks took place at the ages of 17, 18, and
21 months. Skin rash, arthralgia, abdominal pain and diarrhea were
seen occasionally on crises. Laboratory evaluation revealed mild micro-
cytic hypochromic anemia (hemoglobin 8–10 g/dL), with a Mentzer
index suggestive of iron-deﬁciency anemia (greater than 13), with no
response to iron supplementation and, during acute attacks, leuko-
cytosis (white blood cell count 23,490–32,280/mm3) with neutrophilia
(67.8–80.9%), increased ESR (61–91 mm/h; normal range: less than
15 mm/h) and CRP (6.27–18.49 mg/dL; normal range: less than
0.5 mg/dL). Clinical and laboratory improvement, though incomplete,
was seen in-between (Table 1).
The patient was extensively studied. Renal and liver functions, as
well as cardiac, ophthalmologic and neurologic evaluations were nor-
mal. Infectious causes, namely virus (HIV1–2, EBV, CMV,HHV6–7), par-
asites (Toxoplasma gondii, Leishmania sp.), and bacteria (Mycobacterium
tuberculosis, atypical mycobacteria, Bartonella henselae, Brucella sp.,
Rickettsia sp., Coxiella burnetii, Erlichia) were ruled out. Child immune
status was normal, ruling out primary immunodeﬁciency disorders like
autoimmune lymphoproliferative syndrome, chronic granulomatous dis-
ease and leukocyte adhesion deﬁciency. Bone marrow and lymph node
examination also excluded lymphoproliferative disease. Autoimmune
evaluation was negative (ANA, ENAs, anti-dsDNA, ANCAs and comple-
ment) excluding autoimmune disease.
SAA increased to 104–510 mg/L (reference range: b6.4 mg/L), and
serum IgA was 2.5–4.9 g/L (normal range: 0.45–1.35 g/L) (Table 1). De-
spite normal serum IgD (less than 22.6 mg/L), HIDS was clinically
suspected. Mutational MVK analysis revealed a homozygous genotype
for a new missense variant p.Arg277Gly (p.R277G) in the patient, and
heterozygous genotypes for the healthy non-consanguineous parents
(Fig. 1). In silico analyses using the SIFT and Polyphen-2 algorithms reveal
respectively a tolerated (Score 0.28) and possibly damaging (Score 0.952)
behavior for the structure and/or function of mevalonate kinase protein.
At the time of diagnosis, short corticosteroid (2 mg/kg/day for
3 days, with tapering in 5 days) and nonsteroidal anti-inﬂammatory
drug (NSAID) courses were given during attacks, with poor beneﬁtsTable. 1
Clinical and laboratory data before and upon the treatment with anakinra.
Laboratory evaluation Before anakinra Upon anak
On crisis Between crises
Hemoglobin (g/dL) 8 8.6 10.3–10.6
WBC count/mm3 32,280 19,390 15,200–18,
Platelets/mm3 849,000 422,000 239,000–40
ESR (mm/h) 120 91 53–104
CRP (mg/dL) 26.81 15.87 8.19–14.8
SAA (mg/L) 510 – 93.4
IgA (g/L) 4.9 3.71 2.12–2.66
IgD (mg/L) b22.6 b22.6 92.7–151.2
Crises Every 2–5 weeks – 7 crises in 1mainly characterized for the decrease of fever duration. On the basis
of frequent crises and subclinical inﬂammation between episodes (ele-
vated CRP, ESR and SAA) (Table 1), subcutaneous (sc) anakinra was
started (2 mg/kg/day) at the age of 3 years. He showed initially a
good response to this treatment, characterized by decrease of frequency
of episodes (only two crises in 5 months) and reduced severity of crisis
(one day of mild fever without malaise; skin rash for 5–7 days, no
lymphadenopathy and hepatosplenomegaly, nor vomiting or diarrhea).
After these ﬁve months of anakinra therapy he restarted with severe
crises and dosewas increased to 3 mg/kg/day sc. Crises were character-
ized by ill appearing, high fevers, skin rash, cervical adenopathy, hepato-
megaly (4 cm), splenomegaly (4 cm), abdominal pain, diarrhea, and
serositis in 2 episodes. During these acute attacks he also had leukocyto-
sis, increased ESR and CRP, and, for the ﬁrst time, a serum IgD rise
(Table 1). Frequently, steroid courses should be added to anakinra to
control these crises. Six months later, anakinra dose was increased to
5 mg/kg/day because of monthly crises and persistent inﬂammatory
markers out of crises. With this scheme severe crises became less fre-
quent, anemia improved with normalization of red blood cell indices
and normal HbA2 level, and, at the same time, there was a normalization
of inﬂammatory markers detected, with normal SAA and CRP; ESR









1 months; 3 times corticosteroid 4 crises in 34 months; 2 times corticosteroid
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performed under anakinra therapy revealed the presence of very few
class-switch CD19 + CD27 + IgD-cells, with excess of B cells exhibiting
the naïve phenotype. Three years later, on anakinra 5 mg/kg/day, the pa-
tient is stable, with few crises and normal or almost normal inﬂammatory
markers most of the time.
3. Discussion
MVK gene is located on chromosome12q24, and around 65 different
mutations have been currently identiﬁed. Most of them are loss-of-
function mutations and are associated with a wide phenotypic spec-
trum, probably related with the residual activity of the patient's
mevalonate kinase enzyme. The extremes of this spectrum are the
HIDS syndrome at the less severe end and the mevalonic aciduria
(MA) at the severest. In HIDS, the residual enzymatic activity varies
from 1% to 10% and it is less than 0.5% in MA (Bader-Meunier et al.,
2011; Korppi et al., 2011; van der Hilst and Frenkel, 2010). However,
within theHIDSphenotype there is no clear relationship among severity
of disease, symptoms onset, number of attacks per year, and a speciﬁc
mutation (van der Hilst and Frenkel, 2010). Interestingly, some families
with HIDS carry at least one of theMVKmutations responsible for MA,
such as p.I268T. On the other hand, the incidence of themost commonly
HIDS-associatedmutation (p.V377I) in Dutch population is signiﬁcantly
higher than would be anticipated based on the number of diagnosed
cases of HIDS in Holland (about 2:100,000 live births) (Lierl, 2007).
This implies that some individuals who are homozygous for this muta-
tion do not develop HIDS. The reason for the differing phenotypes pro-
duced by this genetic variant has not been still determined (Lierl, 2007).
In this patient, mutational MVK analysis revealed a homozygous geno-
type for a new missense variant p.Arg277Gly (p.R277G), while the
healthy non-consanguineous parents were heterozygous. The p.R277G
MVK variant has not been previously reported in the medical literature
and registered neither in the INFEVERS database nor in the online avail-
able database dnSNP, supporting reasonably its exclusion as a rare gene
polymorphism. The p.R277G variant has not been registered in different
database of genomic Diversity (1000 Genome Project, HapMap, etc.).
In this database are included samples from different ancestries and ori-
gins, including samples from the Iberian Peninsula. In the authors' per-
sonal experience, this particular MVK variant has not been detected in
approximately 1400 MVK alleles analyzed during the past decade,
fromboth Spanish patients (n approx: 600) and controls (n: 100). Inter-
estingly, in the INFEVERS database two different MVKmutations affect-
ing the same amino acid residue have been registered: i) the p.R277C
MVK mutation detected in a patient with mevalonic aciduria (Houten
et al., 2000) and ii) the p.R277H MVK mutation detected in a family
with HIDS (Hospach et al., 2005). These evidences strongly suggest
that the amino acid residue arginine at position 277 could be an impor-
tant residue for the enzymatic activity of the proteinmevalonate kinase.
The activity of themevalonate kinase, not performed,would be relevant
in helping to demonstrate the importance of this mutation and a possi-
ble explanation for the severity of this patient's disease. Additionally,
the bioinformatics analyses of the novel MVK variant, using the SIFT
and Polyphen-2 algorithms, predict a tolerated and possibly damaging
behavior, respectively.
Mevalonate kinase is an essential enzyme for isoprenoid metabo-
lism, which produces cholesterol, ubiquinone and dolichol, which play
a role in protein isoprenylation (van der Hilst and Frenkel, 2010). How
mevalonate kinase deﬁciency leads to inﬂammation is incompletely
understood, with two major hypotheses for the disease's pathogenesis:
the accumulation of products upstream of the step catalyzed by the
mevalonate kinase enzyme, such as mevalonic acid, or the marked
reduction of products downstream this step, including cholesterol or
isoprenoids (Stojanov and Kastner, 2005). These latter compounds are
involved in the post-translational isoprenylation (farnesylation or
geranylation) of several important intracellular signaling molecules,including the Ras, Rho/Rac, and Rab families of small guanosine
triphosphate-binding proteins. In an in vitro system, accentuated IL-
1β secretion by leukocytes from HIDS patients can be reversed by the
addition of farnesol or geranyl–geraniol, leading support to the second
hypothesis (Stojanov and Kastner, 2005). Both the isoprenoid deﬁcien-
cy and the mevalonate accumulation hypotheses predict symptoms
worsening with decreased mevalonate kinase enzymatic activity
(Stojanov and Kastner, 2005). Accordingly, the level of mevalonic acid
excreted in urine is admitted to be of diagnostic value.
HIDS clinical picture is believed to reﬂect enhanced proinﬂammato-
ry cytokine production by mononuclear cells (Lachmann et al., 2011;
Touitou and Koné-Paut, 2008). A defect in lymphocyte apoptosis has
also been detected (van der Hilst and Frenkel, 2010). The proinﬂamma-
tory state, with subsequent tumor necrosis factor alpha (TNF-α) and in-
terleukin 1-beta (IL-1β) overproduction, is believed to induce the
disease's characteristic attacks and inﬂammatory markers (Lachmann
et al., 2011; Touitou and Koné-Paut, 2008). Even between attacks,
about half the patients have signs of inﬂammation with SAA and CRP
elevation, although much lower than during attacks (van der Hilst and
Frenkel, 2010), as reported in this patient.
The principal laboratory ﬁnding in HIDS is a persistent elevation of
polyclonal IgD. However, IgD values can be within normal range, espe-
cially until 3 years of age (van der Hilst and Frenkel, 2010). In fact, it
has been reported that symptoms may precede the increase in serum
IgD concentrations by years, and the levels of IgD do not correlate
with the frequency or severity of attacks (Saulsbury, 2003). Increased
serum IgA levels have been found in N80% of patients with HIDS
(Klasen et al., 2001). Likewise, this patient had normal serum IgD
(until 3 years old) and elevated IgA levels since disease's onset. Klasen
IS et al. provided evidence that elevated IgA levels in HIDS is due to a
systemic stimulation of the immune systemwith a continuous stimula-
tion of the IgA system (Klasen et al., 2001). Interestingly, hyper-IgA in
HIDS is mostly represented by hyper-IgA1, suggesting bone marrow as
the main production site of IgA. The signiﬁcant correlation between
IgA or IgA1 and IgD suggests a collective stimulatory site (Klasen et al.,
2001). In this patient, the peripheral blood B cell immunophenotyping
revealed the presence of very few class-switch CD19 + CD27 + IgD-
cells, with excess of B cells exhibiting the naïve phenotype. These cells
may be responsible for the IgD production. We believe that the virtual
absence of IgA1 producing plasmocytes may be explained by their pref-
erential location in the bone marrow.
Currently, there is no evidence-based treatment available for HIDS
and targeted therapies are needed (van der Burgh et al., 2012).
Etanercept, a TNF-α inhibitor, and anakinra, the recombinant form of
the human IL-1 receptor antagonist, are reasonable alternatives in the
treatment of HIDS, as these cytokines seem to play a central role in
acute HIDS attacks. Inﬂiximab, a humanized monoclonal antibody
against TNF-α, and tocilizumab, a humanized monoclonal antibody
against the IL-6 receptor, might also be thinkable alternatives. So far,
some children have been successfully treated with etanercept and
with different anti-IL-1 drugs (Bodar et al., 2011; Caorsi et al., 2012;
Galeotti et al., 2012; Hoffman, 2009; Rigante et al., 2006). If either of
these treatments are not effective a switch to the other can be consid-
ered, because some patients have a good response to anti-IL1 drugs
but not to etanercept, and vice versa (Caorsi et al., 2012; van der Hilst
and Frenkel, 2010). Severe unresponsive cases of MA could be consid-
ered for allogeneic stem cell transplantation (van der Burgh et al.,
2012). In the case here described only a partial clinical response to
usual doses of anakinra (2 mg/kg/day) was initially observed, requiring
step-up doses reaching 5 mg/kg/day to achieve a more controlled dis-
ease (inﬂammatory markers, less number of crises and severe ones
with need for steroid therapy). These ﬁndings, along with severity of
the clinical picture and persistently elevated inﬂammatory parameters,
including SAA, are consistent with the presence of a severe phenotype.
Advances in our understanding of HIDS pathogenesis may allow
explaining the differences in treatment response and its possible
220 J.A. Santos et al. / Gene 542 (2014) 217–220relation to the different genotypes. Further studies are needed to evalu-
ate a relation MVK genotype, enzyme activity and clinical phenotype,
and to deﬁne best therapeutic strategies for each patient.
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